Klicken Sie hier, um die Auftaktveranstaltung zum Bayer-Kongress zu sehen
Bemerkenswerte Bayer-Abstracts, die auf der Sitzung präsentiert werden, sind unten verfügbar. Bitte beachten Sie: Alle Abstract-Informationen sind bis Montag, 8. Februar, 17:00 Uhr ET/23:00 Uhr MEZ gesperrt.
- Abstract #239: Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial
- Abstract #240: Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial
- Abstract #217: Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world stud
- Abstract #TPS266: DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801) – A randomized phase III double-blind, placebo- controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
- Abstract #105: Synergistic antitumor efficacy of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft model
- Abstract #135: Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration- refractory prostate cancer (mCRPC): Final efficacy and safety results
- Abstract #TPS182: A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress
- Abstract #48: Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH
- Abstract #98: Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer
- Abstract #TPS175: Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial
- Abstract #136: Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence